Injection of nanoparticle has proven effective in mouse models, researchers say
Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, the most aggressive type of skin cancer. Their innovative approach has so far proven effective in preventing the development of melanoma in mouse models and in treating primary tumors and metastases that result from melanoma.
The focus of the research is on a nanoparticle that serves as the basis for the new vaccine. The study was led by Prof. Ronit Satchi-Fainaro, chair of the Department of Physiology and Pharmacology and head of the Laboratory for Cancer Research and Nanomedicine at TAU’s Sackler Faculty of Medicine, and Prof. Helena Florindo of the University of Lisbon while on sabbatical at the Satchi-Fainaro lab at TAU; it was conducted by Dr. Anna Scomparin of Prof. Satchi-Fainaro’s TAU lab and postdoctoral fellow Dr. João Conniot. The results were published on August 5 in Nature Nanotechnology.
Melanoma develops in the skin cells that produce melanin or skin pigment. “The war against cancer in general, and melanoma in particular, has advanced over the years through a variety of treatment modalities, such as chemotherapy, radiation therapy and immunotherapy; but the vaccine approach, which has proven so effective against various viral diseases, has not materialized yet against cancer,” says Prof. Satchi-Fainaro. “In our study, we have shown for the first time that it is possible to produce an effective nano-vaccine against melanoma and to sensitize the immune system to immunotherapies.”
The researchers harnessed tiny particles, about 170 nanometers in size, made of a biodegradable polymer. Within each particle, they “packed” two peptides — short chains of amino acids, which are expressed in melanoma cells. They then injected the nanoparticles (or “nano-vaccines”) into a mouse model bearing melanoma.
“The nanoparticles acted just like known vaccines for viral-borne diseases,” Prof. Satchi-Fainaro explains. “They stimulated the immune system of the mice, and the immune cells learned to identify and attack cells containing the two peptides — that is, the melanoma cells. This meant that, from now on, the immune system of the immunized mice will attack melanoma cells if and when they appear in the body.”
The researchers then examined the effectiveness of the vaccine under three different conditions.
First, the vaccine proved to have prophylactic effects. The vaccine was injected into healthy mice, and an injection of melanoma cells followed. “The result was that the mice did not get sick, meaning that the vaccine prevented the disease,” says Prof. Satchi-Fainaro.
Second, the nanoparticle was used to treat a primary tumor: A combination of the innovative vaccine and immunotherapy treatments was tested on melanoma model mice. The synergistic treatment significantly delayed the progression of the disease and greatly extended the lives of all treated mice.
Finally, the researchers validated their approach on tissues taken from patients with melanoma brain metastases. This suggested that the nano-vaccine can be used to treat brain metastases as well. Mouse models with late-stage melanoma brain metastases had already been established following excision of the primary melanoma lesion, mimicking the clinical setting. Research on image-guided surgery of primary melanoma using smart probes was published last year by Prof. Satchi-Fainaro’s lab.
“Our research opens the door to a completely new approach — the vaccine approach — for effective treatment of melanoma, even in the most advanced stages of the disease,” concludes Prof. Satchi-Fainaro. “We believe that our platform may also be suitable for other types of cancer and that our work is a solid foundation for the development of other cancer nano-vaccines.”
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- ITIH5, a p53-responsive gene, inhibits the growth and metastasis of melanoma cells by downregulating the transcriptional activity of KLF4on May 2, 2021 at 12:35 am
ITIH5, a member of the inter-α-trypsin inhibitory (ITI) gene family, acts as a putative tumour-suppressor gene in many cancers. However, its role and the regulatory mechanism in melanoma are still ...
- Stories of Loss and Survival with Melanomaon April 30, 2021 at 9:12 am
My story of loss began in August 2004 when my wife was diagnosed with melanoma. An unnoticed spot on her lower back scabbed over and bled. A biopsy in the office came back as testing positive as ...
- Dear Dr. Roach: Agent Orange linked to some cancers, but not melanomaon April 29, 2021 at 3:00 am
Your recent column on melanoma piqued my interest. My husband was exposed to Agent Orange in Vietnam in 1968. He had a melanoma on his neck removed ...
- AHN building new melanoma, skin cancer centeron April 28, 2021 at 9:15 pm
Jessica Rogowicz grew up playing outside and spending lots of time in the sun including yearly beach vacations in Ocean City, Md.
- Olatec Therapeutics Announces Results Showing Dapansutrile Reduces Tumor Growth in a Mouse Model of Melanomaon April 28, 2021 at 11:48 am
Olatec Therapeutics LLC (Olatec) today announced the first publication from its preclinical studies with dapansutrile in selected cancer models.
- Dr. Davies on Managing Melanoma During the COVID-19 Pandemicon April 28, 2021 at 10:25 am
Davies, MD, PhD, discusses the management of patients with melanoma during the COVID-19 pandemic. Michael A. Davies, MD, PhD, the Anne and John Mendelsohn Chair in Cancer Research; professor and chair ...
- Alkermes commences trial of nemvaleukin monotherapy for melanomaon April 28, 2021 at 9:33 am
Alkermes has initiated a global Phase II ARTISTRY-6 trial of its lead immuno-oncology candidate nemvaleukin alfa in melanoma patients who have previously received anti-PD- (L)1 therapy. Nemvaleukin is ...
- Academic Alliance in Dermatology talks Melanoma Awareness Monthon April 28, 2021 at 6:11 am
Melanoma Awareness Month kicks off in May. At Academic Alliance in Dermatology, we firmly believe that no lives should ever be lost to malignant melanoma. Our staff’s mission is clear: eliminate ...
- Melanoma Research Alliance Announces $8.1 million in Research Awardson April 27, 2021 at 7:30 am
The Melanoma Research Alliance, the largest non-profit funder of melanoma research, is proud to announce $8.1 million in funding for 34 new research a ...
- High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimenson April 26, 2021 at 5:00 pm
Mutations in the BRAF gene at or near the p. V600 locus are informative for therapy selection, but current methods for analyzing FFPE tissue DNA generally have a limit of detection of 5% variant ...
via Bing News